Abstract |
The prognostic value of serum beta 2 microglobulin (s beta 2m) measured at entry, at plateau and at 3-monthly follow-up times has been assessed for patients in the Medical Research Council's 4th and 5th Myelomatosis Trials. Analysis of 1014 patients confirmed the value of presentation s beta 2m of predicting survival in the short term but showed that predictive value was lost for subsequent survival in those patients who had survived for at least 2 years. However, measurements of s beta 2m taken during follow-up were predictive of subsequent survival. The predictive power of these follow-up measurements was very similar to that for the presenting measurement, and again they were only of value in predicting survival in the next 2 years.
|
Authors | J Cuzick, B L De Stavola, E H Cooper, C Chapman, I C MacLennan |
Journal | British journal of haematology
(Br J Haematol)
Vol. 75
Issue 4
Pg. 506-10
(Aug 1990)
ISSN: 0007-1048 [Print] England |
PMID | 2119793
(Publication Type: Journal Article)
|
Chemical References |
- Hemoglobins
- Immunoglobulin Heavy Chains
- Immunoglobulin Light Chains
- beta 2-Microglobulin
- Creatinine
- Calcium
|
Topics |
- Calcium
(blood)
- Creatinine
(blood)
- Hemoglobins
(analysis)
- Humans
- Immunoglobulin Heavy Chains
(analysis)
- Immunoglobulin Light Chains
(analysis)
- Multiple Myeloma
(blood, drug therapy, mortality)
- Prognosis
- Time Factors
- beta 2-Microglobulin
(analysis)
|